Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. buff.ly/4cyYKwB #ASX PharmAust

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: investorhub.pharmaust.com/investment-off…. Thank you for your continued support! 🌟 #PharmAust

📸 Highlights from the MND Australia Global Day Event at Parliament House! We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙 #MNDAustralia #FightMND #MNDGlobalDay

🚀 Exciting News! PharmAust has been granted SME status by the European Medicines Agency, unlocking financial benefits and support to accelerate our monepantel (MPL) program for MND/ALS. A significant step forward! #Biotech #PharmAust #MND #ALS

📢 Exciting news! Monepantel has been accepted onto the prestigious HEALEY ALS Platform Trial in the US! 🌟 This partnership is a significant step forward in developing a viable treatment for ALS. We're committed to supporting the ALS community in Australia and globally. #PAA

PharmAust completes Share Purchase Plan, raising $7.8M, far exceeding the $2M target! With $17.8M total from SPP and Placement, we're primed to advance the HEALEY ALS Platform Trial. Huge thanks to our shareholders for their incredible support! #PharmAust #ASX #PAA

PharmAust has completed its share purchase plan, raising $7.8m and far exceeding the initial target of $2m, further bolstering its balance sheet after a recent $10m placement to institutional and sophisticated investors. buff.ly/46gUO1k PharmAust #ASX $PAA

Exciting news! Dr. Michael Thurn, was recently featured on the "Let's Talk MND" podcast hosted by Jane Simpson. 🎙️Hear about PAA's efforts to advance Monepantel as a treatment for ALS and MND. #biotech #neurodegenerative #innovation open.spotify.com/show/4WmtdSBhy…

🌟 Exciting News! Join PharmAust at the TechKnow Invest Roadshow in Sydney on July 30th and Melbourne on July 31st. Connect with industry leaders in the tech and medtech sectors. Don't miss out! 🚀 #TechKnow2024 #PharmAust #MedTech

PharmAust presented at the Techknow Invest Roadshow! 🚀🎤 Check out our presentation on advancing ALS/MND treatments with monepantel. Watch here: youtube.com/watch?v=2zh9wJ…

PharmAust (ASX: PAA) is featured in Stockhead's Health & Biotech Investor Guide FY2025! 🌟 Proud to be recognized among top healthcare innovators. Dive into the guide to learn more about our journey and future prospects. 📈🔬 #PharmAust #Biotech #ALS #Healthcare #ASX

PharmAust announces positive interim results from the Open-Label Extension study in ALS! 4 months of monepantel treatment shows promising survival benefits and slowed disease progression. We're committed to advancing this crucial research. #ALS #biotech #innovation

PharmAust has released promising interim results from its ongoing open-label extension study of its lead drug monepantel to treat Amyotrophic Lateral Sclerosis. buff.ly/3AIZAcA PharmAust #ASX $PAA

🚀 Excited to launch our new podcast, "Neural Threads"! 🧬 Hosted by CSO Nicky Wallis, dive into the latest in biotech with a focus on neurodegenerative diseases & innovative therapies. youtube.com/watch?v=u-oLwD…

PharmAust’s breakthrough drug monepantel is generating buzz with its promising results in treating MND/ALS, potentially transforming the future for patients and offering investors a lucrative opportunity. buff.ly/4cIwPtO PharmAust #ASX $PAA

Excited to see Dr. Susan Mathers present the promising Phase 1 results of monepantel in ALS patients at the MND Research Symposium in Melbourne. A crucial step forward in improving lives worldwide! 🌍🔬 #ALS #MND #Research #Pharmaust

Exciting to see The Australian feature Pharmaust in an article about our recent Morgans coverage! 🚀 The potential upside for monepantel is gaining recognition. Check out the full story in The Australian: theaustralian.com.au/business/stock… #Pharmaust #Biotech #ALS #TheAustralian

📢 PharmAust is thrilled to share an exclusive interview with Dr. Michael Thurn ahead of our participation at the Spark+ Australian Equities Day in Singapore on Sept 20! 🔗 Watch the full interview & register: linkedin.com/feed/update/ur…

📎PharmAust submits Orphan Medicinal Product Designation request to EMA for monepantel, targeting ALS! If granted, this would provide regulatory support & 10 years of EU market exclusivity. Decision expected in Dec 2024. Exciting times ahead! 🌍 #PharmAust #Biotech #ALS

PharmAust has submitted a request for orphan medicinal product designation to the European Medicines Agency for its lead drug monepantel for the treatment of amyotrophic lateral sclerosis (ALS). buff.ly/4gqOXLN PharmAust #ASX $PAA